|

MARCH 4, 2015

WSGR represents Pharmacyclics in $21 billion sale to AbbVie

Wilson Sonsini Goodrich & Rosati provided counsel to Sunnyvale-based Pharmacyclics Inc. in its $21 billion sale to AbbVie Inc. The North Chicago-based biopharmaceutical company is purchasing Pharmacyclics' flagship product, Imbruvica, as a result of the sale. Imbruvica treats tumors that affect blood, bone marrow and lymphatic systems. AbbVie will pay $261.25 per share, in an offer the includes both cash and stock.

Wilson Sonsini used a team that included San Francisco-based partners Robert Ishii and Denny Kwon and associate Derek Liu, along with Palo Alto-based partners Scott McCall, Ivan Humphreys and Miranda Biven, who also works in San Diego. Partner Michael Hostetler, who works out of San Diego and Houston, and Washington, D.C.-based partner Scott Sher provided assistance.